Novel strategies to manage CAR-T cell toxicity

Area of Science:

• Immunology
• Cellular Biology
• Oncology

Background:

• Immune-related adverse events (irAEs) from chimeric antigen receptor (CAR)-T cell therapy cause significant morbidity and healthcare costs.
• Current management strategies like IL-6R blockade and corticosteroids are insufficient for all irAEs, necessitating novel approaches.
• Understanding the cellular mechanisms underlying irAEs is crucial for developing safer CAR-T cell therapies.

Purpose of the Study:

• To review current management of CAR-T cell-associated toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• To explore novel T cell engineering strategies and druggable targets for mitigating CAR-T cell-induced toxicity.
• To identify methods for uncoupling cytokine-mediated toxicity from CAR-T cell function, persistence, and memory formation.

Main Methods:

• Review of current therapeutic strategies for managing irAEs.
• Analysis of T cell and myeloid cell signaling pathways, metabolism, and differentiation states.
• Exploration of novel CAR-T cell engineering approaches, including low-affinity CARs, on-off switches, and adaptor systems.

Main Results:

• Existing treatments for irAEs are not universally effective and do not prevent progression.
• Targeting CAR or cytokine signaling pathways transiently offers potential for managing toxicity.
• Novel T cell engineering strategies can decouple toxicity from CAR-T cell efficacy.

Conclusions:

• Developing safer CAR-T cell therapies requires a deeper understanding of irAE mechanisms.
• Transient targeting of signaling pathways and advanced T cell engineering hold promise for reducing CAR-T cell toxicity.
• Future research should focus on innovative strategies to improve the safety profile of CAR-T cell treatments.